Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-04-05

FDA Approved: BEPOTASTINE BESILATE OPHTHALMIC SOLUTION 1.5% — Original Application (Alembic Pharmaceuticals Limited)

View source ↗

Summary

FDA approved BEPOTASTINE BESILATE OPHTHALMIC SOLUTION 1.5% from Alembic Pharmaceuticals as an original application for the treatment of itching associated with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Bepotastine Besilate Ophthalmic Solution 1.5% (bepotastine besilate ophthalmic solution 1.5%)

Snippet

ORIG AP for BEPOTASTINE BESILATE OPHTHALMIC SOLUTION 1.5% (BEPOTASTINE BESILATE OPHTHALMIC SOLUTION 1.5%)